WORCESTER, Mass., Oct. 26, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has made five poster presentations at the 11th Annual Canadian Diabetes Association/Canadian Society of Endocrinology and Metabolism Professional Conference and Annual Meeting (CDA/CSEM) (www.diabetes.ca) in Vancouver, British Columbia, October 24-27, 2007, and three poster presentations at the 7th Annual Diabetes Technology Meeting (www.diabetestechnology.org) in San Francisco, California, October 25-27.
The Company has made the following presentations at both the CDA/CSEM Meeting and the Diabetes Technology Meeting:
* 6-Month Study on the Safety and Efficacy of Generex Oral-lyn(tm)
Administered At Lunchtime in Juvenile Type-1 DM Subjects
Maintained on Basal Glargine Insulin and Pre-Breakfast and
Pre-Dinner Regular Insulin
* Comparison of Metabolic Control of Pre-Prandial S.C. Regular
Insulin Versus Prandial Split Doses of an Oral Insulin in Adult
Type-1 Diabetes Mellitus Subjects Receiving Basal S.C. Twice
Daily Isophane Insulin (NPH)
* Near Normalization of Metabolic Control in Type-1 DM Using
Conventional Insulin Therapy and a 13-Point Method Designed to
Enhance Compliance
The posters were authored by Doctors Jaime Guevara-Aguirre, Marco Guevara-Aguirre, Jeannette Saavedra, all of the Institute of Endocrinology IEMYR, Quito, Ecuador, and Gerald Bernstein, the Company's Vice-President for Medical Affairs.
The Company has made the following additional presentations at the Diabetes Technology Meeting featuring Glucose RapidSpray(tm), the Company's proprietary glucose spray product:
* Glucose RapidSpray(tm): A New Device to Control Neuroglycopenia
and Consequent Request for Food
The poster was authored by Professor Paolo Pozzilli, University Campus Bio-Medico, Rome, Italy with Antonio Picardi, Manon Yeganeh Merola, Maria Altomare, Natalia Visalli, Elisa Cipponeri, and Chiara Guglielmi.
* Glucose RapidSpray(tm) and Diet as Tools for Body Weight Control
The poster was authored by Professor Paolo Pozzilli, University Campus Bio-Medico, Rome, Italy with Manon Yeganeh Khazrai, Maria Altomare, Natalia Visalli, Laura Cipolloni, Anna Rita Maurizi, and Chiara Guglielmi.
"We are pleased that these abstracts, featuring the Company's products, are being accepted at several important international scientific symposia," said Rose C. Perri, the Company's Chief Operating Officer.
The CDA/CSEM is attended by educators, clinicians and scientists sharing expertise, ideas and experiences in diabetes and endocrine disorders. The Annual Diabetes Technology Meeting showcases developments in technology for patients with diabetes.
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. In June, 2007 the Company announced the commencement of a global Phase III clinical trial of Generex Oral-lyn(tm) in the third quarter of 2007 with patient dosing to commence before yearend. For more information, visit the Generex website at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.